Results 341 to 350 of about 137,826 (378)
Some of the next articles are maybe not open access.
BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality
Cancer Research, 2023AbstractThe concept of “BRCAness” was first described in 2004 to define the situation in which a homologous recombination repair (HRR) defect in a tumor relates to and phenocopies BRCA1 or BRCA2 loss-of-function mutations. Soon after the discovery of synthetic lethality of PARP1/2 inhibitors in BRCA1- or BRCA2-deficient cells, McCabe and colleagues ...
Junko Murai, Yves Pommier
openaire +2 more sources
Evaluation of Homologous Recombination Deficiency in Ovarian Cancer
Current Treatment Options in OncologyHomologous recombination deficiency (HRD) is an important biomarker guiding selection of ovarian cancer patients who will derive the most benefit from poly(ADP-ribose) polymerase inhibitors (PARPi). HRD prevents cells from repairing double-stranded DNA damage with high fidelity, PARPis limit single-stranded repair, and together these deficits induce ...
Rubina Ratnaparkhi +3 more
semanticscholar +3 more sources
IEEE journal of biomedical and health informatics, 2023
Homologous recombination deficiency (HRD) is a well-recognized important biomarker in determining the clinical benefits of platinum-based chemotherapy and PARP inhibitor therapy for patients diagnosed with gynecologic cancers.
Yibo Zhang +4 more
semanticscholar +1 more source
Homologous recombination deficiency (HRD) is a well-recognized important biomarker in determining the clinical benefits of platinum-based chemotherapy and PARP inhibitor therapy for patients diagnosed with gynecologic cancers.
Yibo Zhang +4 more
semanticscholar +1 more source
JCO Precision Oncology, 2023
PURPOSE Homologous recombination deficiency (HRD) is a well-described phenotype of some prostate cancers; however, current biomarkers for HRD are imperfect and rely on detection of single gene alterations in the homologous recombination repair (HRR) pathway, which may not capture the complexity of HRD biology.
Landon C. Brown +8 more
openaire +2 more sources
PURPOSE Homologous recombination deficiency (HRD) is a well-described phenotype of some prostate cancers; however, current biomarkers for HRD are imperfect and rely on detection of single gene alterations in the homologous recombination repair (HRR) pathway, which may not capture the complexity of HRD biology.
Landon C. Brown +8 more
openaire +2 more sources
Journal of Clinical Oncology
PURPOSE Cancers with homologous recombination deficiency (HRD) can benefit from platinum salts and poly(ADP-ribose) polymerase inhibitors. Standard diagnostic tests for detecting HRD require molecular profiling, which is not universally available ...
E. Bergstrom +6 more
semanticscholar +1 more source
PURPOSE Cancers with homologous recombination deficiency (HRD) can benefit from platinum salts and poly(ADP-ribose) polymerase inhibitors. Standard diagnostic tests for detecting HRD require molecular profiling, which is not universally available ...
E. Bergstrom +6 more
semanticscholar +1 more source
Exploiting Homologous Recombination Deficiency in TNBC
Current Breast Cancer Reports, 2017Since the identification of the BRCA1 and BRCA2 genes over two decades ago, considerable progress has been made in elucidating the role of defective DNA repair in the pathogenesis of triple-negative breast cancer (TNBC). Here, we discuss the significance of recent advances in our understanding of homologous recombination (HR) deficiency, emerging HR ...
Alexey Aleshin, Melinda L. Telli
openaire +1 more source
Homologous Recombination Deficiency in Breast Cancer: A Clinical Review
JCO Precision Oncology, 2017BRCA1 and BRCA2 germline mutation–associated breast cancers are known to be deficient in the process of homologous recombination and often respond favorably to drugs targeting this important DNA repair pathway. There is emerging evidence that a significant proportion of patients with BRCA1/ BRCA2 wild-type breast cancer are also deficient in ...
Wendie D, den Brok +6 more
openaire +2 more sources
[Homologous recombination deficiency and PARP inhibitors in therapeutics].
Bulletin du cancer, 2022PARP inhibitors are effective in different types of tumors such as ovarian, breast, prostate and pancreatic cancer. Many studies are in progress and may lead to prescription evolution. PARP inhibitors prescription is almost reserved to patients with a constitutional BRCA mutation or a somatic BRCA alteration or a tumor with a deficiency in homologous ...
Hélène, Salaün +7 more
openaire +1 more source
Homologous Recombination Deficiency (HRD) in Hematological Malignancies
Blood, 2022Nikhil Sahajpal +4 more
openaire +1 more source